Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. CanaRx Services Inc
WARNING LETTER
•CanaRx Services Inc•February 28, 2019

CanaRx Services Inc – FDA Warning Letter, Feb 28, 2019

Record Details

On February 26, 2019, the FDA issued a Warning Letter to Mr. Gregory Anthony Howard, addressing CanaRx Services Inc/CRX Intl and its affiliates. The FDA determined that CanaRx is causing the introduction of unapproved new drugs and misbranded drugs into interstate commerce, violating sections 301(a), 301(d), and 505(a) of the FD&C Act.

CanaRx operates as a prescription drug provider, contracting with U.S. employers to provide prescription drugs to employees by acting as a broker between foreign pharmacies and employer-sponsored health insurance plans. CanaRx accepts U.S. prescriptions, facilitates their reissue by foreign physicians, and then foreign pharmacies ship the drugs directly to U.S. employees. The use of a templated invoice with a disclaimer about potential differences in medication appearance indicates a design to substitute FDA-approved drugs with unapproved ones.

These products are considered "new drugs" under section 201(p) of the FD&C Act because they lack general recognition of safety and effectiveness for their labeled uses and have no FDA-approved applications. Their introduction into interstate commerce thus violates sections 301(d) and 505(a). The FDA highlighted significant health risks, including the lack of safeguards for recalls, potential for patient confusion and medication errors due to different trade names and dosages, and the risk of receiving subpotent, super

Company
CanaRx Services Inc
Inspection date
February 28, 2019
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Thomas (TJ) Christl (Office Director)
View Company Profile

ID · 6acc53eb-66b8-4748-8134-4e62b810b59e

Violation Codes10
21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 321(g)(1)21 U.S.C. 321(p)21 U.S.C. 353(b)(1)(A)21 U.S.C. 352(f)(1)21 U.S.C. 352(f)(2)21 CFR 201.521 CFR 201.10021 CFR 201.115

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore CanaRx Services Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.